Interleukin-6 Levels In Patients Research Articles

Serum levels of Interleukin-6 in patients with Idiopathic Carpal Tunnel Syndrome: A case control study in Najaf Province

Background: Carpal Tunnel Syndrome (CTS) is a disease caused by a compression of the median nerve at the wrist within carpal canal that lead to multiple symptoms as paraesthesia, numbness and pain sensation in the median distribution fingers. If untreated, it leads to sensation loss, thenar muscle weakness and atrophy. It is most frequent peripheral neuropathy of upper limbs and is most predominant in female gender. The pathogenesis of CTS is yet unknown, and the majority of conditions are idiopathic. Interleukin 6 is a cytokine that has multiple functions including pro-inflammatory and anti-inflammatory or regenerative actions. The impact of serum inflammatory cytokines on incidence and severity of CTS is still unclear. Aim of the study: this study aims to correlate the clinical severity of CTS and the serum interleukin 6 concentrations. Patients and methods: This is a case control study which involved 140 participants who were categorized into 70 patients with CTS and 70 healthy persons according to clinical assessment and nerve conduction study results. After that, the participants were divided to normal, mild, moderate and severe groups according to Boston carpal tunnel questionnaire (BCTQ). Then, a blood sample was taken from each participant to assess serum interleukin 6 levels. A statistical analysis by SPSS was done for the collected data. Results: The study has shown that there was no significant correlation between serum interleukin 6 levels and the clinical severity score of CTS (P value >0.05). Conclusion: It has been concluded that serum interleukin 6 levels did not have an impact on incidence and clinical severity of CTS and that its role in CTS is yet unclear.

Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention

BackgroundCytokines play a potential role in atherosclerosis pathogenesis and progression. We investigated the association of interleukin-6 (IL-6) with the angiographic severity of coronary artery disease (CAD).MethodsThree hundred ten angiografically diagnosed CAD patients and 210 controls were enrolled in this study. CAD patients were stratified according to IL-6 cut-off value into high levels IL-6 group (≥ 9.5 pg/mL) and low levels IL-6 group (< 9.5 pg/mL). The severity of CAD was assessed according to Gensini score (GS), artery stenosis degree and the number of vessels involved. The mean age was 60.3 ± 11.0 years.ResultsThe level of IL-6 in patients was increased compared to controls and ranged from 1.5 to 3640.0 pg/mL. High levels of IL-6 were significantly associated with high levels of GS (> 40) but not with stenosis degree and vessel score. GS levels were significantly more elevated in patients with high levels of IL-6 group than in low IL6 levels patients (60.6 ± 39.5 vs 46.7 ± 37.2; p = 0.027). The analysis of the ROC curve performed in myocardial infarction patients showed that IL-6 (AUC: 0.941 (CI 95% 0.886, 0.997; p < 0.001) could be a powerful predictor marker in evaluating the infarct size after myocardial infarction when compared to myonecrosis biomarkers.ConclusionsIL-6 levels were associated with the severity of CAD assessed by the GS. Based on the highest levels of IL-6 measured in patients with STEMI, our study strongly suggests that IL-6 could be a powerful marker in evaluating the myocardial necrosis.Trial registrationClinicalTrials.gov Number: NCT03075566 (09/03/2017).

C‑reactive protein and related predictors in soft tissue sarcoma (Review).

C-reactive protein (CRP) is a useful predictor of poor survival in patients with several types of cancer because inflammation is strongly associated with cancer progression. The production of CRP in hepatocytes appears to be primarily induced at the transcriptional level following the elevation of circulating interleukin-6 (IL-6), which is produced by various cell types, including cancer cells and cancer-associated fibroblasts. Serum CRP levels are associated with serum IL-6 levels in patients with soft tissue sarcoma (STS). Additionally, patients with elevated CRP levels had worse oncological outcomes than those with normal CRP levels. It has been attempted to combine CRP levels with other inflammatory or immune markers, and the utility of this has been demonstrated. Therefore, a novel treatment strategy should be developed for patients with STS with elevated CRP levels. The present review aimed to clarify the role of CRP levels and related tools in predicting clinical outcomes in patients with STS.

Relationship between salivary levels of interleukin-8 and HbA1c in patients with type 2 diabetes.

Diabetes mellitus is a metabolic disease, which genetic and environmental factors play a role in its pathogenesis. Cytokines as important elements in the immune system have diverse expressions in different individuals and societies and are effective in the pathogenesis of diabetes. This study investigated the relationship between blood sugar control and salivary levels of interleukin-8 (IL-8) in patients with type 2 diabetes. This cross-sectional study was conducted on 73 subjects (35 diabetic and 38 healthy individuals). Unstimulated saliva samples were collected and the correlation between IL-8, as an inflammatory marker and HbA1c (Haemoglobin A1C) was studied. The levels of IL-8 and HbA1c were significantly higher in the patient group than control group (p < .001, p < .001, respectively). There was not any relationship between salivary IL-8 levels and glycemic control levels (p = .629). Also, there was no remarkable difference between men and women in terms of the levels of IL-8 and HbA1c saliva (p = .524, p = .998, respectively). Although the salivary IL-8 levels were higher in the diabetic patients, blood sugar control did not significantly affect cytokine concentrations. Increased salivary levels of IL-8 in patients with type 2 diabetes could be a basis for risk assessment, prevention and treatment of diabetes-related complications.

Evaluating the plasma interleukin-1 beta and interleukin-8 levels in patients with chronic obstructive pulmonary diseases following treatment with allogeneic mesenchymal stem cell derived from umbilical cord tissues and platelet rich plasma

Chronic obstructive pulmonary disease (COPD) is a common disease which negatively affects living quality and longevity of patients. Unfortunately, current COPD treatments are not radical. COPD is characterized by persistent neutrophil infiltrations mediated by inflammatory cytokines including interleukin (IL)-1β and IL-8 in the airway. Mesenchymal stem cells (MSCs) have been proven to suppress inflammation, modulate the immune system and can be regenerative. Allogeneic MSCs have been used to treat COPD patients across the world and produced positive clinical outcomes. In this study, we evaluated plasma IL-1β and IL-8 concentrations in 10 stage-D COPD patients before being transplanted with allogeneic MSCs derived from umbilical cord tissues (UC-MSCs) activated by platelet-rich plasma (PRP) and at 4 follow- ups (after 1, 3, 7, 12 months), as well as determined their associations with COPD clinical and sub-clinical parameters. Plasma IL-1β and IL-8 concentrations were measured using Multiplex Immunoassay. We found that plasma IL-8 levels were significantly reduced from 3.2 to 1.9 pg/ml after 12 months of treatment which is accompanied by the notable decrease in C-reactive protein (CRP). Exacerbation episodes were significantly decreased from 3 to 1. Plasma IL-1β levels were positively correlated with IL-8 levels and white blood cell (WBC) levels. Parallel measurements of plasma IL-1β and IL-8 may help assess the disease progression of COPD patients after the treatment with UC- MSCs and PRP. Blockage of IL-1β or IL-8 could be a valid strategy for the prevention and control of COPD.

Elevated interleukin-10 levels in patients with ocular toxoplasmosis.

In elderly patients, ocular toxoplasmosis is one of the most common etiologies of uveitis, which should be differentially diagnosed from ocular lymphoma, another common pathology of uveitis in older adults. The high level of interleukin (IL)-10 and an IL-10/IL-6 ratio higher than 1 (>1.0) are helpful parameters to diagnose ocular lymphoma. In this study, we used aqueous humor samples to detect 4 cases of ocular toxoplasmosis in patients with high levels of IL-10 and an IL-10/IL-6 ratio higher than 1. Our results show that ocular toxoplasmosis may be associated with increased cytokine levels in aqueous humor.

Sivelestat sodium for treatment of patients with COVID-19-associated acute respiratory distress syndrome in intensive care unit: a single-center retrospective cohort study

To investigate the effect of sivelestat sodium on survival, oxygenation index, and serum markers for infection in critically ill patients with COVID-19-associated acute respiratory distress syndrome (ARDS). This retrospectively study was performed among the critically ill patients with COVID-19-associated ARDS admitted in the intensive care unit (ICU) at Nanfang Hospital, Southern Medical University. We collected the clinical data of the patients on the first day of ICU admission and on the day of discharge and laboratory tests results of interleukin-6 (IL-6), C-reactive protein (CRP) and procalcitonin (PCT) and oxygenation index on days 1, 3 and 7 following ICU admission. Propensity-score matching was used to match the patients receiving sivelestat sodium to those without the treatment. Cox proportional hazards model and linear regression analysis were used to assess the association of sivelestat sodium treatment with in-hospital mortality and the length of hospital stay. A total of 199 patients with COVID-19-associated ARDS patients were included for data analysis. After propensity-score matching PSM, 35 patients receiving sivelestat sodium were matched to 70 patients without the treatment. Treatment with of sivelestat sodium was not associated with the reduction of in- hospital mortality (P=0.36), prolonged ICU stay (P=0.39), hospital stay (P=0.68) or improved oxygenation index (P>0.05) of the patients. No significant difference was found in serum CRP or PCT levels between the patients with and without sivelestat sodium treatment, but a significant reduction in IL-6 level was found in sivelestat sodium group (P=0.016). Sivelestat sodium treatment is not correlated with the reduction of mortality or length of hospital stay, but is associated with reduced serum IL-6 level in patients with COVID-19-associated ARDS.

High expression of IL6 and decrease in immune cells in COVID-19 patients combined with myocardial injury.

Myocardial injury, as a serious complication of coronavirus disease-2019 (COVID-19), increases the occurrence of adverse outcomes. Identification of key regulatory molecules of myocardial injury may help formulate corresponding treatment strategies and improve the prognosis of COVID-19 patients. Gene Set Enrichment Analysis (GSEA) was conducted to identify co-regulatory pathways. Differentially expressed genes (DEGs) in GSE150392 and GSE169241 were screened and an intersection analysis with key genes of the co-regulatory pathway was conducted. A protein-protein interaction (PPI) network was constructed to screen for key regulatory genes. Preliminarily screened genes were verified using other datasets to identify genes with consistent expression. Based on the hierarchical cluster, we divided the patients from GSE177477 into high- and low-risk groups and compared the proportion of immune cells. A total of 267 COVID-19 patients from the Zhejiang Provincial Hospital of Chinese Medicine from December 26, 2022, to January 11, 2023, were enrolled to verify the bioinformatics results. Univariate and multivariate analyses were performed to analyze the risk factors for myocardial injury. According to high-sensitivity troponin (hsTnI) levels, patients with COVID-19 were divided into high- and low-sensitivity groups, and interleukin 6 (IL6) expression and lymphocyte subsets were compared. Patients were also divided into high and low groups according to the IL6 expression, and hsTnI levels were compared. Interleukin signaling pathway and GPCR ligand binding were shown to be co-regulatory pathways in myocardial injury associated with COVID-19. According to the hierarchical cluster analysis of seven genes (IL6, NFKBIA, CSF1, CXCL1, IL1R1, SOCS3, and CASP1), patients with myocardial injury could be distinguished from those without myocardial injury. Age, IL6 levels, and hospital stay may be factors influencing myocardial injury caused by COVID-19. Compared with COVID-19 patients without myocardial injury, the levels of IL6 in patients with myocardial injury increased, while the number of CD4+ T cells, CD8+ T cells, B cells, and NK cells decreased (P<0.05). The hsTnI levels in COVID-19 patients with high IL6 levels were higher than those in patients with low IL6 (P<0.05). The COVID-19 patients with myocardial injury had elevated IL6 expression and decreased lymphocyte counts. IL6 may participate in myocardial injury through the interleukin signaling pathway.

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure.

Background: The inhibition of sodium-glucose co-transporter 2 (SGLT-2) has been shown to be beneficial in the treatment of diabetic and non-diabetic patients with heart failure. The underlying mechanisms are incompletely understood. The present prospective study investigates for the first time the effect of empagliflozin on various soluble markers of inflammation in patients with reduced ejection fraction (HFrEF). Methods: We included 50 inpatients with HFrEF and diabetes mellitus type 2. A total of 25 patients received a therapy with the SGLT-2-inhibitor empagliflozin in addition to standard medication; the other 25 patients did not receive empagliflozin and were considered the control group. Quality of life, functional status and soluble immunological parameters in serum were assessed at baseline and after 3 months. Results: The baseline characteristics of both groups revealed no significant differences. Patients on empagliflozin demonstrated a significant improvement in the Minnesota living with heart failure questionnaire (baseline 44.2 ± 20.2 vs. 24 ± 17.7; p < 0.001), in distance in the 6-min walk test (baseline 343 ± 145 m vs. 450 ± 115 m; p < 0.001) and in soluble interleukin-6 level (baseline 21.7 ± 21.8 pg/mL vs. 13.7 ± 15.8 pg/mL; p = 0.008). There was no significant change of these or other parameters in the control group (p > 0.05 each). Conclusions: The empagliflozin-induced improvement of quality of life and functional capacity in patients with HFrEF and type 2 diabetes mellitus is accompanied by a substantial reduction of interleukin-6 levels. Thus, anti-inflammatory effects may contribute to the benefits of SGLT-2-inhibitors in heart failure.

Evaluation of the effect of vitamin D on the salivary and serum levels of interleukin-8 in patients with periodontitis stage I and II grade A.

Evaluation of the effect of vitamin D on the salivary and serum levels of interleukin-8 in patients with periodontitis stage I and II grade A.

A systematic review and meta-analysis of changes in interleukin-8 levels in malaria infection

The roles of interleukin-8 (IL-8) in malaria are inconsistent and unclear. This study synthesised evidence for differences in IL-8 levels in patients with malaria of various levels of severity. Relevant studies were searched in Scopus, MEDLINE, Embase, CENTRAL and PubMed from inception to 22 April 2022. Pooled mean differences (MDs) and 95% confidence intervals (CIs) were estimated using the random effects model. Of 1083 articles retrieved from the databases, 34 were included for syntheses. The meta-analysis revealed increased IL-8 levels in individuals with uncomplicated malaria compared with those without malaria (P = 0.04; MD, 25.57 pg/mL; 95% CI, 1.70 to 49.43 pg/mL; I2, 99.53, 4 studies; 400 uncomplicated malaria, 204 uninfected controls). The meta-analysis revealed comparable levels of IL-8 between the two groups (P = 0.10; MD, 74.46 pg/mL; 95% CI, −15.08 to 164.0 pg/mL; I2, 9.03; 4 studies; 133 severe malaria cases, 568 uncomplicated malaria cases). The study found evidence of increased IL-8 levels in individuals with malaria compared with those without malaria. However, no differences were found in IL-8 levels between patients with severe and non-severe malaria. Further research is needed to investigate the IL-8 cytokine levels in patients with malaria of different levels of severity.

Evaluation of serum adipocytokine and interleukin-18 levels in patients with epilepsy

Objective: Epilepsy is a neurological disease characterized by recurrent seizures. The underlying pathophysiological mechanisms in epilepsy are not fully known. Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy.&#x0D; &#x0D; Method: Our study was established as three groups. I: Epilepsy patients receiving antiepileptic therapy (n=30), II: Newly diagnosed epilepsy patients (n=30) and III: Control group (n=30). Serum adipocytokine and IL-18 levels were measured by enzyme-linked immunoassorbent assay method.&#x0D; &#x0D; Results: It was determined that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received topiramate treatment and did not receive antiepileptic therapy compared to the control group. Serum glucose, total protein, cholesterol and albumin concentrations of patients who received antiepileptic treatment were decreased compared to the control group (p0.05). It was found that the body mass index (BMI) ratio of epilepsy patients who received antiepileptic treatment decreased and was significant compared to the control group and the group that did not receive treatment (p

Up-conversion Luminescence System for Quantitative Detection of IL-6.

Interleukin-6 (IL-6) is a very important cytokine and an early predictor of survival in febrile patients (eg, patients with COVID-19). With the outbreak of the COVID-19 in the world, the significance of medical detection of interleukin 6 has gradually become prominent. A method to point-of-care(POCT) diagnosis and monitoring of IL-6 levels in patients is urgently needed. In this work, an up-conversion luminescence system (ULS) based on upconverting nanoparticles (UCNs) for quantitative detection of IL-6 was designed. The ULS consists of Micro Controller Units (MCU), transmission device, laser, image acquisition module, Bluetooth module, etc. Through hardware system acquisition and image software algorithm processing, we obtain a limit of detection (LOD) of IL-6 at 1 ng/mL, and the quantitative range is from 1 to 200 ng/mL. The system is handheld and has great detection accuracy. The detection time is 10 minutes. In addition, the system can access mobile device terminals (smartphones, personal computers, etc.) or 5G cloud servers via Bluetooth and WIFI. Patients and family members can view medical data through mobile terminals, and the data stored in the 5G cloud server can be used for edge computing and big data analysis. It is suitable for the early diagnosis of infectious diseases such as COVID-19 and has good application prospects.

Rheumatoid arthritis and the proinflammatory cytokine IL-17.

Rheumatoid arthritis (RA) is the most common inflammatory joint disease. Various proinflammatory cytokines are involved in the pathogenesis of this chronic disorder. It is characterized by the presence of autoantibodies, such as rheumatoid factor and antibodies against citrullinated peptides. The present study focuses on investigation of possible association between the proinflammatory cytokine interleukin 17 and anti-CCP, anti-MCV, and anti-CarP antibodies seropositivity in RA patients. To assess serum levels of interleukin 17 (IL-17) in patients with rheumatoid arthritis and healthy controls (HC) and to investigate the relationship between IL-17 and anti-cyclic citrullinated protein (anti-CCP) antibodies, antimutated citrullinated vimentin (anti-MCV) antibodies, and anti-carbamylated protein (anti-CarP) antibodies in patients with RA. Forty-seven patients diagnosed with rheumatoid arthritis and 44 healthy controls were included in the study. Serum IL-17 levels were examined in all participants. Anti-CCP, anti-MCV, and anti-CarP antibodies were tested in the group of RA patients. The mean serum level of IL-17 in RA patients was higher (12.8pg/ml) than that in healthy controls (7.9pg/ml), but the difference was not statistically significant (p=0.276). No significant correlation was observed between anti-CCP (+/-) and IL-17 (rs=0.162, p=0.380), and between anti-MCV (+/-) and IL-17 (rs=0.157, p=0.340). A significant positive correlation of moderate value was reported between anti-CarP (+/-) and IL-17 (rs=0.388, p=0.015). The present study demonstrated that the IL-17 serum levels in RA patients were increased compared to healthy controls. No correlation was found between ACPA immunological markers and IL-17 levels in patients with RA. A positive correlation was found between anti-CarP antibodies and IL-17 in the patients' group. The increased level of IL-17 is suggestive of its possible role in the pathogenesis of CarP positive RA patients.

Salivary irisin level is higher and related with interleukin-6 in generalized periodontitis.

Irisin plays an important role in energy homeostasis, inflammation, glucose, and lipid metabolism, and it is shown to have relations with many inflammatory diseases. The aim of the study was to determine saliva and serum irisin and IL-6 levels in patients with stage III/grade B periodontitis compared with individuals with healthy periodontium. Twenty patients with stage III grade B periodontitis (P) and 20 periodontally healthy subjects (control; C) were included in this study. Clinical periodontal measurements were recorded. Saliva and serum levels of irisin and interleukin-6 (IL-6) were analyzed by enzyme-linked immunosorbent assay. Salivary irisin and IL-6 levels were significantly higher in the periodontitis group (p < 0.001, p = 0.002, respectively). Furthermore, serum IL-6 levels were found significantly higher in the periodontitis group compared with controls (p = 0.011). There was no significant difference between the periodontitis and control for serum irisin levels (p > 0.05). Significant positive correlations were found between all periodontal parameters and salivary irisin and IL-6 (p < 0.05) and also between BMI and saliva and serum IL-6 (respectively; r = 0.530, r = 0.329, p < 0.05). There was a positive correlation between salivary irisin and IL-6 (r = 0.369, p < 0.05). Monitoring of salivary irisin and IL-6 might be potential biomarker for predicting the susceptibility to periodontitis. Scientific rationale for the study: Irisin is a novel adipomyokine that has played an important role in energy homeostasis, glucose and lipid metabolism, angiogenesis, immunity, and inflammation. Irisin is involved in the pathogenesis of diseases affecting many body systems. IL-6, another adipomyokine, is a major inflammatory mediator and homeostatic regulator of glucose and lipid metabolism and is associated with periodontitis. No studies investigated the relationship between advanced periodontal disease, irisin, and IL-6 together. The salivary irisin and IL-6 levels were significantly higher and positively correlated in patients with periodontitis relative to healthy controls. Furthermore, serum IL-6 levels were significantly increased in patients with periodontitis. The study shows that irisin and IL-6 can be candidate salivary biomarkers for periodontitis and predict to periodontal status.

Effect of topical aloe vera gel on gingival crevicular fluid interleukin-1 beta and interleukin-17 levels in patients with chronic periodontitis; A double-blind split-mouth randomized clinical trial

Introduction: Cytokines play a prominent role in the induction of periodontal diseases. Aloe vera can ameliorate periodontal disease considering its anti-inflammatory and antibacterial effects. Objectives: This study investigated the effect of topical aloe vera gel, associated with scaling and root planing (SRP), on interleukin-1 (IL-1) and interleukin-17 (IL-17) of gingival crevicular fluid (GCF) levels in chronic periodontitis patients. Patients and Methods: This study recruited 20 patients diagnosed with moderate to severe chronic periodontitis (with probing pocket depths of ≥5 mm). The control group subjects underwent only SRP; the test group subjects underwent SRP, followed by topical aloe vera gel application. Periodontal clinical parameters, including probing depth (PD), clinical attachment level (CAL) and gingival index (GI), were determined; GCF levels of IL-1 and IL-17 were determined using the enzyme-linked immunosorbent assay (ELISA) at baseline and one month postoperatively. Results: There were significant decreases in periodontal clinical parameters in both groups compared to the baseline. The test group exhibited a significant decrease in interleukin levels compared with the control group as follows; interleukin-1 beta (IL-1β) (control; 61.78±14.54, test; 43.06±10.99 ng/mL) (P&lt;0.001), IL-17 (control; 81.33±16.66, test; 57.04±16.26 ng/mL) (P&lt;0.001). Conclusion: Topical aloe vera gel in combination with SRP significantly improved clinical parameters of periodontitis and decreased IL-1β and IL-17 GCF levels. Trial Registration: The trial protocol of the present study was approved by the Iranian registry of Clinical Trials (identifier: IRCT20100412003690N11; https://en.irct.ir/trial/44975; ethical code #IR.TBZMED.REC.1398.1113).

Assessment of Depression and Its Correlation with Serum Levels of Interleukin-6 in Patients on Maintenance Hemodialysis.

Depression is the most common psychiatric disorder in patients on hemodialysis. An imbalance between proinflammatory and anti-inflammatory cytokines is thought to play a role in the pathogenesis of depression in patients on dialysis. We undertook this study to assess the correlations of the proinflammatory cytokine interleukin 6 (IL-6) and the anti-inflammatory cytokine IL-10 with depression in patients on maintenance hemodialysis. This cross-sectional observational study was carried out at our hospital, a tertiary care referral government teaching hospital, over 2 years. Depression was assessed using the Becks Depression Inventory score. A higher cutoff of >16 was taken for a diagnosis of depression. Clinical, demographic, and laboratory parameters were analyzed. Cytokines were assessed using enzyme-linked immunosorbent assays. Eighty patients satisfied the inclusion criteria. The prevalence of depression in our study was 41.5%. Depression was more common in those who were unemployed and/or illiterate. Mild depression was found in patients from the upper-lower and lower-middle classes, but severe depression was seen in lower-economic classes. Serum levels of IL-6 showed a positive correlation with the severity of depression. Depression was common in patients on maintenance hemodialysis. High levels of serum IL-6 were observed in those with depression. Depression in patients on maintenance hemodialysis is associated with a considerable risk of mortality.

Comparative Study of Salivary Interleukin–8 (IL-8) in Patients with Oral Cancer, Potentially Malignant Disorders, and Tobacco Users

Background: Interleukin 8 (IL-8) or CX-CL8 is a powerful chemoattractant chemokine molecule and an inflammatory and angiogenesis-promoting cytokine, which acts as a biomarker in saliva in patients with tobacco users, oral cancers, and potentially malignant disorders. Aims and Objective: To evaluate and compare salivary IL-8 levels in patients with tobacco users, oral cancer, and potentially malignant disorders and healthy individuals using ELISA (enzyme-linked immunosorbent assay). Materials and Method: Eighty samples were grouped into four sub-groups, with 20 samples in each group: Group I: 20 oral cancer patients; Group II: 20 potentially malignant disorders; Group III: 20 tobacco users; Group IV: 20 control subjects. A sample of unstimulated saliva of 5 mL was collected from the selected individuals based on the exclusion and inclusion criteria. Saliva was centrifuged at 3500 revolutions per minute (rpm), and ELISA for IL-8 was carried out in saliva, stored at –4°C. Results: IBM Statistical Package for Social Sciences (SPSS) for Windows 11, Version 23.0 (Armonk, New York: IBM Corp) software was used for the analysis of data. Using one-way analysis of variance and Tukey’s test for post-hoc analysis, the significant difference in the multi-variate analysis was determined. The mean value of salivary IL-8 levels in Groups I, II, II, and IV was 1055.7, 1074.0, 857.9, and 781.7, respectively. The P value between the groups is 0.77 (p &gt; 0.05), which is statistically not significant. Conclusion: This study found that tobacco users have greater salivary IL-8 levels than individuals with potentially malignant diseases and oral malignancies and healthy patients.

Interleukin-10 levels in patients with alcoholic liver disease

Interleukin-10 levels in patients with alcoholic liver disease

Short Communication: Cloning, production and responses of the sMTL-13 protein (13 kDa lectin secretion) Mycobacterium tuberculosis against Interleukin 6

Abstract. Agus R, Purnamasari WOS, Parura RD, Silang F, Massi MN. 2022. Short Communication: Cloning, production and responses of the sMTL-13 protein (13 kDa lectin secretion) Mycobacterium tuberculosis against Interleukin 6. Biodiversitas 23: 6208-6212. The Bacillus Calmette-Guérin (BCG) vaccine protected effect against meningitis and disseminated Tuberculosis TB in children. However, it does not prevent primary infection and reactivation of latent pulmonary infection. Therefore, an effective vaccine is needed to prevent tuberculosis. One of the potentials is the sMTL-13 protein (13 kDa lectin secretion), which causes an increase in interleukin 6 (IL-6) as a proinflammatory cytokine and shows high titers in the serum of TB patients. This study aimed to clone, express and evaluate the sMTL-13 recombinant protein. The research steps were ligation of Rv1419 to pQE-30Xa, transformation to Escherichia coli BL-21, and production of recombinant protein with IPTG induction. Furthermore, immunoreactivity tests with the serum of TB patients and healthy serum using ELISA. The results showed that the PCR product Rv1419 showed a band of 474 bp and white colonies as a recombinant clone of pQE-30Xa-Rv1419. The production of sMTL-13 recombinant protein has been successfully carried out and produces 13 kDa protein. The results of the immunoreactivity test showed that the serum level of IL-6 in patients with active TB was 84.22 pg/mL and the serum level of IL-6 in healthy people was 63.74 pg/mL.